SCHEMBL6651977

SCHEMBL6651977

c1ccc2c(-c3cscn3)nccc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 2/20 0.46
KDM4B O94953 2/20 0.46
KDM5C P41229 2/20 0.46
KDM5B Q9UGL1 2/20 0.46
KDM4E B2RXH2 5/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
GPR55 Q9Y2T6 1/20 0.44
MAPT P10636 3/20 0.44
KMT2A Q03164 2/20 0.44
GLA P06280 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PLAU P00749 2/20 0.43
CYP2A6 P11509 1/20 0.43
F12 P00748 1/20 0.43
NCF1 P14598 1/20 0.43
NOS3 P29474 1/20 0.43
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29923403 0.77 PLAU (0.60) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL199273 0.77 PLAU (0.60) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL7777776 0.75 IDO1 (0.48) KDM4ENPC1RAB9AMAPTKMT2A
SCHEMBL30522769 0.75 PLAU (0.58) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL2899853 0.75 KMT2A (0.52) KDM4AKDM4BKDM5CKDM5BKDM4E
SCHEMBL934818 0.74 KDM4E (0.50) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL13978866 0.73 PLAU (0.56) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL12223316 0.73 PLAU (0.56) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL20349433 0.72 TDO2 (0.56) KDM4ENPC1RAB9AL3MBTL1GPR55
SCHEMBL12112873 0.71 MAPT (0.58) KDM4ENPC1RAB9AL3MBTL1GPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303021-B1 COMPOUNDS FOR THE TREATMENT OF CANCER UNIV TENNESSEE RES FOUND (US) 2018-12-19 EP disclosed
EP-2301538-B1 Compounds for nonsense suppression, and methods for their use PTC THERAPEUTICS INC (US) 2015-05-20 EP disclosed
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-12-30 US disclosed
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 EP disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors CYP17A1, CYP21A2, HSD17B1 KDM4A 996/4885KDM4B 1042/4885KDM5C 379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.